These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 31879181

  • 41. Design, synthesis, and evaluation of substituted nicotinamide adenine dinucleotide (NAD+) synthetase inhibitors as potential antitubercular agents.
    Wang X, Ahn YM, Lentscher AG, Lister JS, Brothers RC, Kneen MM, Gerratana B, Boshoff HI, Dowd CS.
    Bioorg Med Chem Lett; 2017 Sep 15; 27(18):4426-4430. PubMed ID: 28827112
    [Abstract] [Full Text] [Related]

  • 42. Identification of 2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-N-phenylpropanamides as a novel class of potent DprE1 inhibitors.
    Whitehurst BC, Young RJ, Burley GA, Cacho M, Torres P, Vela-Gonzalez Del Peral L.
    Bioorg Med Chem Lett; 2020 Jun 15; 30(12):127192. PubMed ID: 32312582
    [Abstract] [Full Text] [Related]

  • 43. In silico approaches and chemical space of anti-P-type ATPase compounds for discovering new antituberculous drugs.
    Santos P, López-Vallejo F, Soto CY.
    Chem Biol Drug Des; 2017 Aug 15; 90(2):175-187. PubMed ID: 28111912
    [Abstract] [Full Text] [Related]

  • 44. Identification of potent indolizine derivatives against Mycobacterial tuberculosis: In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies.
    Venugopala KN, Chandrashekharappa S, Deb PK, Al-Shar'i NA, Pillay M, Tiwari P, Chopra D, Borah P, Tamhaev R, Mourey L, Lherbet C, Aldhubiab BE, Tratrat C, Attimarad M, Nair AB, Sreeharsha N, Mailavaram RP, Venugopala R, Mohanlall V, Morsy MA.
    Int J Biol Macromol; 2024 Aug 15; 274(Pt 2):133285. PubMed ID: 38925196
    [Abstract] [Full Text] [Related]

  • 45. In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies of substituted 1,2,4-oxadiazole analogues against Mycobacterium tuberculosis.
    Deb PK, Al-Shar'i NA, Venugopala KN, Pillay M, Borah P.
    J Enzyme Inhib Med Chem; 2021 Dec 15; 36(1):869-884. PubMed ID: 34060396
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. MoS2-Calix[4]arene Catalyzed Synthesis and Molecular Docking Study of 2,4,5-Trisubstituted Imidazoles As Potent Inhibitors of Mycobacterium tuberculosis.
    Raghu MS, Pradeep Kumar CB, Prasad KNN, Prashanth MK, Kumarswamy YK, Chandrasekhar S, Veeresh B.
    ACS Comb Sci; 2020 Oct 12; 22(10):509-518. PubMed ID: 32806898
    [Abstract] [Full Text] [Related]

  • 48. Assays, surrogates, and alternative technologies for a TB lead identification program targeting DNA gyrase ATPase.
    Humnabadkar V, Madhavapeddi P, Basavarajappa H, Sheikh MG, Rane R, Basu R, Verma P, Sundaram A, Mukherjee K, de Sousa SM.
    J Biomol Screen; 2015 Feb 12; 20(2):265-74. PubMed ID: 25300873
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. 5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides: synthesis, in vitro antimycobacterial activity, cytotoxicity, and isocitrate lyase inhibition studies.
    Sriram D, Yogeeswari P, Senthilkumar P, Naidu G, Bhat P.
    J Enzyme Inhib Med Chem; 2010 Dec 12; 25(6):765-72. PubMed ID: 20569083
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Identification of novel selective Mtb-DHFR inhibitors as antitubercular agents through structure-based computational techniques.
    Sharma K, Neshat N, Sharma S, Giri N, Srivastava A, Almalki F, Saifullah K, Alam MM, Shaquiquzzaman M, Akhter M.
    Arch Pharm (Weinheim); 2020 Feb 12; 353(2):e1900287. PubMed ID: 31867798
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.